mProX™ Human PLK3 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1222-KX459	Magic™ Human PLK3 in Vitro Assay	Human		Kinase Assay

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;DU145

Target Classification

Kinase Cell Lines

Target Research Area

Cancer Research;CNS Research

Related Diseases

Parkinson Disease 6, Autosomal Recessive Early-Onset; Anal Squamous Cell Carcinoma

Gene ID

Human:1263

UniProt ID

Human:Q9H4B4

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

PLK3, or polo-like kinase 3, has been found to have various applications in different fields. In the context of swine influenza virus, PLK3 facilitates viral replication by phosphorylating the viral NP protein. In glioblastoma, PLK3 is inhibited by TUBA1A to suppress mitotic progression and tumor growth. In another study, PLK3 promotes the proneural-mesenchymal transition in glioblastoma through transcriptional regulation of C5AR1, which could be a potential therapeutic target. Additionally, PLK3 has been identified as a potential biomarker for biodosimetry following ionizing radiation exposure, and it is negatively regulated by FOXO3A in STZ diabetic stress-treated pancreatic Œ≤ cells, affecting mitophagy and insulin secretion. These findings highlight the diverse roles of PLK3 in viral replication, tumor growth, radiation response, and diabetes.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human PLK3 Stable Cell Line (S01YF-1023-PY79). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Jordan Garcia (Verified Customer)

How does PLK3 contribute to renal ischemia-reperfusion injury? Sep 11 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

PLK3 is involved in oxidative stress-induced DNA damage and tubular epithelial cell apoptosis in renal ischemia-reperfusion injury, suggesting its potential as a therapeutic target. Sep 11 2022

chat Taylor Smith (Verified Customer)

What is the role of PLK3 in uterine serous cancer? Feb 22 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

PLK3 amplification is linked to tumor immune microenvironment and adjuvant treatment outcomes in uterine serous cancer, indicating its significance in cancer progression. Feb 22 2020

Published Data

Fig.1 Prostate cancer cell proliferation was decreased through the knockdown of Plk3.

The reduction of Plk3 expression in DU145 cells, achieved through transfection with siRNA2 and siRNA4 targeting Plk3, was distinctly observed, as compared to cells transfected with control siRNA. Subsequently, the impact of Plk3 knockdown on the viability of DU145 cells was assessed through MTS assay.

Ref: Lin, Chunhao, et al. "Polo-like kinase 3 is associated with poor prognosis and regulates proliferation and metastasis in prostate cancer." Cancer Management and Research (2019): 1517-1524.

Pubmed: 30863161

DOI: 10.2147/CMAR.S176762

Research Highlights

Yu, Shuo. et al. "PLK3 promotes the proneural-mesenchymal transition in glioblastoma via transcriptional regulation of C5AR1." Molecular biology reports, 2023.
Recent studies have shown the potential significance of polo-like kinase 3 (PLK3) in tumor cell functioning and its role in promoting cell growth. PLK3 has been implicated in various cancers and may serve as a prognostic factor. This study aims to examine the involvement of PLK3-dependent proneural-mesenchymal transition (PMT) in the treatment of glioblastoma (GBM). This research seeks to elucidate PLK3's role in GBM therapy and its potential as a therapeutic target.
Yu, Shuo. et al. "PLK3 promotes the proneural-mesenchymal transition in glioblastoma via transcriptional regulation of C5AR1." Molecular biology reports, 2023.
Pubmed: 37568042 DOI: 10.1007/s11033-023-08716-7

Liu, Zhenqiu. et al. "Candidate biomarkers and persistent transcriptional responses after low and high dose ionizing radiation at high dose rate." International journal of radiation biology, 2023.
This study describes the development of an integrated time and dose model aimed at understanding the changes in gene expression and identifying biomarkers for biodosimetry after exposure to low- and high-dose irradiations at high dose rates. The model combines both time and dose parameters and explores the dynamics of gene expression alterations. The results of this study have the potential to aid in radiation risk assessment and inform on future biodosimetry practices.
Liu, Zhenqiu. et al. "Candidate biomarkers and persistent transcriptional responses after low and high dose ionizing radiation at high dose rate." International journal of radiation biology, 2023.
Pubmed: 37549410 DOI: 10.1080/09553002.2023.2241897